ArticleJournal of ovarian research2026
Long-term outcomes of fertility preservation counseling in women of reproductive age prior to gonadotoxic therapy.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAs survival rates for reproductive-aged women with cancer improve, the importance of fertility preservation (FP) prior to gonadotoxic chemotherapy has increased. This study evaluated long-term FP outcomes by comparing return rates and clinical pregnancy rates across FP strategies -oocyte and embryo cryopreservation and GnRH agonist use-and analyzed longitudinal ovarian reserve changes via serum anti-Müllerian hormone (AMH).
resultsAmong 399 women analyzed, breast cancer was the most common diagnosis (72.4%). Serum AMH declined profoundly at 6 months post-chemotherapy (3.07 to 0.08 ng/mL, p < 0.01), with partial recovery at 12 months (0.30 ng/mL), remaining significantly below baseline throughout 60-month follow-up. Longitudinal AMH data were available only for GnRH agonist-treated patients, precluding direct comparison with untreated patients. The return rate for pregnancy counseling was highest in the embryo cryopreservation group (63.4%). Total CPR among returning patients were significantly higher in the oocyte cryopreservation (70.5%) and embryo cryopreservation (69.2%) groups versus the counseling-only group (28.5%) (p = 0.020 and p = 0.014, respectively). Notably, all cryopreservation patients also received GnRH agonists; comparisons therefore reflect GnRH agonist plus cryopreservation versus GnRH agonist alone versus no active FP. GnRH agonist use alone did not show a significant advantage over counseling only.
conclusionsChemotherapy is associated with a substantial and lasting reduction in ovarian reserve despite GnRH agonist co-treatment. Oocyte and embryo cryopreservation were associated with significantly higher CPR compared with counseling or GnRH agonist use alone, though causal inference is precluded by the retrospective design. The independent effect of GnRH agonists on ovarian reserve could not be fully assessed due to the absence of a GnRH agonist-naive control group with longitudinal follow-up. Cancer patients represent a distinct FP population with higher return rates than social FP cohorts, underscoring the importance of cancer-specific evidence for counseling. These findings support early FP counseling and suggest cryopreservation offers reproductive benefits beyond GnRH agonist use alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.